Eterna Therapeutics receives Nasdaq delisting notice for failure to regain compliance with equity rule

Ernexa Therapeutics Inc.

On Sept 17, 2024, Nasdaq determined Eterna did not meet the extension terms to demonstrate compliance with the Minimum Stockholders' Equity Rule (stockholders' equity < $2.5M as of Dec 31, 2023).
Trading of ERNA common stock will be suspended on Sept 26, 2024 unless a hearing request is filed by Sept 24, 2024.
Company intends to timely request a hearing with Nasdaq's Hearings Panel to appeal the determination; a stay will be in effect pending decision.
Hearings typically scheduled 30-45 days after request; panel decision within 30 days of hearing; no assurance of success.
If appeal fails or no request, a Form 25-NSE will be filed, removing ERNA from Nasdaq listing and registration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.